Xilio director granted 10,000 stock options
Xilio Therapeutics director Cheryl R. Blanchard received a grant of stock options covering 10,000 shares of common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Xilio Therapeutics director Cheryl R. Blanchard received a grant of stock options covering 10,000 shares of common stock. These options have an exercise price of $8.40 per share and expire on April 14, 2036.
The award was granted on April 15, 2026 and will vest in three equal installments on April 15, 2027, April 15, 2028 and April 15, 2029, as long as she continues to serve the company through each vesting date. Following this grant, she holds 10,000 options directly.
Insider Trade Summary
Grant/Award: 10,000 shares
Grant/Award
1 txn
Insider
Blanchard Cheryl R
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 10,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to buy) — 10,000 contracts (Direct)
Footnotes (1)
- F1. The option was granted on April 15, 2026 and will vest in three equal installments on April 15, 2027, April 15, 2028 and April 15, 2029, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date.
Key Figures
Option grant size: 10,000 options
Exercise price: $8.40 per share
Expiration date: April 14, 2036
+2 more
5 metrics
Option grant size
10,000 options
Stock Option (right to buy) granted to director
Exercise price
$8.40 per share
Exercise price of stock option grant
Expiration date
April 14, 2036
Option expiration for granted award
Post‑grant options held
10,000 options
Total options held following transaction
Vesting schedule
3 equal annual installments
Vesting on April 15, 2027, 2028 and 2029
Key Terms
Stock Option (right to buy), exercise price, vesting, Common Stock, +1 more
5 terms
Stock Option (right to buy) financial
"security_title: Stock Option (right to buy)"
exercise price financial
"conversion_or_exercise_price: 8.4000"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"will vest in three equal installments on April 15, 2027, April 15, 2028 and April 15, 2029"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
Common Stock financial
"underlying_security_title: Common Stock"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
Form 4 regulatory
"INSIDER FILING DATA (Form 4)"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Xilio Therapeutics (XLO) report for Cheryl R. Blanchard?
Xilio Therapeutics reported a grant of stock options to director Cheryl R. Blanchard for 10,000 shares of common stock. The options were awarded as compensation, not an open‑market purchase or sale, and give her the right to buy shares at a fixed exercise price.
What are the key terms of Cheryl R. Blanchard’s new XLO stock options?
Blanchard received options to buy 10,000 Xilio Therapeutics shares at an exercise price of $8.40 per share. The options are set to expire on April 14, 2036, providing a long‑dated right to acquire common stock if she chooses to exercise.
How do Cheryl R. Blanchard’s Xilio Therapeutics options vest over time?
The 10,000 stock options vest in three equal installments over three years. Vesting occurs on April 15, 2027, April 15, 2028 and April 15, 2029, and each tranche requires Blanchard to remain in service with Xilio Therapeutics through the relevant vesting date.
Is Cheryl R. Blanchard’s Form 4 transaction a stock purchase or a compensation grant?
The Form 4 shows a compensation grant, not a market purchase. Blanchard acquired a stock option award with a transaction code A, which indicates a grant, award, or other acquisition, giving her rights to buy 10,000 shares at $8.40, subject to vesting conditions.
How many Xilio Therapeutics options does Cheryl R. Blanchard hold after this grant?
After this transaction, Blanchard holds 10,000 stock options directly, according to the filing’s post‑transaction holdings figure. These options all relate to Xilio Therapeutics common stock and are governed by the specified exercise price, expiration date and vesting schedule.
AI-generated analysis. How Rhea-AI works. Not financial advice.
